Sarcoidosis Demonstrated by FDG PET Imaging With Negative Findings on Gallium Scintigraphy
- 1 March 2005
- journal article
- case report
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 30 (3) , 193-195
- https://doi.org/10.1097/00003072-200503000-00013
Abstract
The manifestations of sarcoidosis are protean and have been well described. Conventionally, gallium-67 scan is used to evaluate sarcoidosis in nuclear medicine. Fluorodeoxyglucose positron emission tomography (FDG PET) has been successfully used in the evaluation of cancers. However, FDG is not a tumor-specific radiotracer and can also accumulate in the sarcoid lesions. We present a case of sarcoidosis, which demonstrated an unremarkable gallium-67 scintigraphy but showed extensive FDG uptake in the chest and the brain on PET imaging.Keywords
This publication has 8 references indexed in Scilit:
- Positron Emission Tomography Can Reveal Abdominal PeriaortitisClinical Nuclear Medicine, 2002
- 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammationSeminars in Nuclear Medicine, 2002
- Clinical Value of [18F]fluoro-Deoxyglucose Positron Emission Tomography for Patients with Fever of Unknown OriginClinical Infectious Diseases, 2001
- Exclusion of Chronic Osteomyelitis With F-18 Fluorodeoxyglucose Positron Emission Tomographic ImagingClinical Nuclear Medicine, 2000
- F-18 FDG Uptake in Breast Infection and InflammationClinical Nuclear Medicine, 2000
- High Fluorine-18 Labeled Deoxyglucose Uptake in SarcoidosisClinical Nuclear Medicine, 1996
- Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomographyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1994
- Whole-body Gallium 67 Scans: Role in Diagnosis of SarcoidosisAmerican Review of Respiratory Disease, 1991